Targeted therapies for soft-tissue sarcomas

References

• Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2006. CA Cancer J. Clin.56, 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Eilber FC, Brennan MF, Eilber FR et al. Validation of the postoperative nomogram for 12-year sarcoma specific death. Cancer101(10), 2270–2275 (2004).
   PubMed Web of Science ®Google Scholar
• Eilber FC, Rosen G, Nelson SD et al. High-grade extremity soft tissue sarcomas factors predictive of local recurrence and its effect on morbidity and mortality. Ann. Surg.237(2), 218–226 (2003).
   PubMed Web of Science ®Google Scholar
• Borden EC, Baker LH, Bell RS et al. Soft tissue sarcomas of adults: state of the translational science. Clin. Cancer Res.9, 1941–1956 (2003).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100, 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Ohanna M, Sobering AK, Lapointe T et al. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol.7(3), 286–294 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer6(9), 729–734 (2006).
   PubMed Web of Science ®Google Scholar
• Okuno SH, Mahoney MR, Bailey HH et al. A multicenter Phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). J. Clin. Oncol.24(S18), 9504 (2006).
   Google Scholar
• Chawla SP, Tolcher AW, Staddon AP et al. Updated results of a Phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J. Clin. Oncol.24(S18), 9505 (2006).
   Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev.18(1), 4–25 (1997).
   PubMed Web of Science ®Google Scholar
• Hu M, Nicolson GL, Trent JC et al. Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors. Cancer95(7), 1569–1576 (2002).
   PubMedGoogle Scholar
• Graeven U, Andre N, Achilles E et al. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J. Cancer Res. Clin. Oncol.125(10), 577–581 (1999).
   PubMed Web of Science ®Google Scholar
• Kuhnen C, Lehnhardt M, Tolnay E et al. Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours. J. Cancer Res. Clin. Oncol.126(4), 219–225 (2000).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.Nature362(6423), 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res.65, 671–680 (2005).
   PubMed Web of Science ®Google Scholar
• Kuenen BC, Tabernero J, Baselga J et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res.9, 1648–1655 (2003).
   PubMed Web of Science ®Google Scholar
• Heymach JV, Desai J, Manola J et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res.10, 5732–5740 (2004).
   PubMed Web of Science ®Google Scholar
• Gasparini G, Longo R, Fanelli M et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J. Clin. Oncol.23(6), 1295–1311 (2005).
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol.23(28), 7135–7142 (2005).
   PubMed Web of Science ®Google Scholar
• Yoo J, Park SY, Kang SJ et al. Altered expression of G1 regulatory proteins in human soft tissue sarcomas. Arch. Pathol. Lab. Med.26(5), 567–573 (2002).
   Google Scholar
• Carlson BA, Dubay MM, Sausville EA et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res.56(13), 2973–2978 (1996).
   PubMed Web of Science ®Google Scholar
• Motwani M, Li X, Schwartz G. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. Clin. Cancer Res.6, 924–932 (2000).
   PubMed Web of Science ®Google Scholar
• Morris DG, Bramwell VHC, Turcotte R et al. A Phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma2006, 1–7 (2006).
   Google Scholar
• Li W, Fan J, Bertino JR. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res.61(6), 2579–2582 (2001).
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Scheu K, Singer S et al. A Phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. J. Clin. Oncol.24(S18), 9523 (2006).
   Google Scholar
• Chen Z, Xia Z, Gu WZ et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer119(12), 2784–2794 (2006).
   PubMed Web of Science ®Google Scholar
• Perez RP, Lewis LD, Beelen AP et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin. Cancer Res.12(23), 7079–7085 (2006).
   PubMed Web of Science ®Google Scholar
• Li Y, Sun X, LaMont JT et al. Selective killing of cancer cells by β-lapachone: direct checkpoint activation as a strategy against cancer. Proc. Natl Acad. Sci.100(5), 2674–2678 (2003).
   PubMed Web of Science ®Google Scholar
• Li C, Nemunaitis J, Senzer N et al. A Phase Ib trial of ARQ 501, a selective checkpoint activator, in combination with docetaxel in patients with advanced solid tumors. J. Clin. Oncol.24(S18), 13053 (2006).
   Google Scholar
• Hymowitz SG, Christmyer HW, Fuh G et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell4(4), 563–571 (1999).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Mendolson DS, Ebbinghaus S et al. A Phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J. Clin. Oncol.24(S18), 3013 (2006).
   PubMedGoogle Scholar
• Schmitt E, Gehrmann M, Brunet M et al. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leuk. Biol.81(1), 15–27 (2007).
   PubMed Web of Science ®Google Scholar
• Terry J, Lubieniecka JM, Kwan W et al. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin. Cancer Res.11(15), 5631–5638 (2005).
   PubMed Web of Science ®Google Scholar
• Sherman ML, Ryan C, Blackstein M et al. Phase 1/2 study of STA-4783, a novel heat shock protein 70 (hsp70) inducer, in combination with paclitaxel in patient with soft tissue sarcomas (STS). J. Clin. Oncol.23(S16), 9069 (2005).
   Google Scholar
• Brujin D, Nap JP, Kessel AG. The (epi)genetics of human synovial sarcoma. Gene Chrom. Cancer46, 107–117 (2007).
   PubMedGoogle Scholar
• Kawaguchi S, Wada T, Ida K et al. Phase I vaccination trial of SYT–SSX junction peptide in patients with disseminated synovial sarcoma. J. Transl. Med.3(1), 1 (2005).
   PubMed Web of Science ®Google Scholar
• Xie Y, Tornkvist M, Aalto Y. Gene expression profile by blocking the SYT–SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT–SSX target gene. Oncogene22, 7628–7631 (2003).
   PubMedGoogle Scholar
• Nagayama S, Fukukawa C, Katagiri T et al. Therapeutic potential of antibodies against FZD10, a cell surface protein, for synovial sarcomas. Oncogene24, 6201–6212 (2005).
   PubMed Web of Science ®Google Scholar
• Kondapalli L, Soltani K, Lacouture ME. The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J. Am. Acad. Dermatol.53, 291–302 (2005).
   PubMedGoogle Scholar
• McArthur GA, Demetri GD, Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J. Clin. Oncol.23, 866–873 (2005).
   PubMed Web of Science ®Google Scholar
• Casali PG, Messina A, Stacchiotti S et al. Imatinib mesylate in chordoma. Cancer101(9), 2086–2097 (2004).
   PubMed Web of Science ®Google Scholar
• Casali PG, Stacchiotti S, Messina A et al. Imatinib mesylate in 18 advanced chordoma patients. J. Clin. Oncol.23(S16), 9012 (2005).
   Google Scholar
• Goy BW, Lee SP, Eilber F et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int. J. Radiat. Oncol. Biol. Phys.39(3), 659–665 (1997).
   PubMed Web of Science ®Google Scholar
• Goy BW, Lee SP, Fu YS et al. Treatment results of unresected or partially resected desmoid tumors. Am. J. Clin. Oncol.21(6), 584–590 (1998).
   PubMedGoogle Scholar
• Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J. Clin. Oncol.24(7), 1195–1203 (2006).
   PubMed Web of Science ®Google Scholar
• Evilevitch V, Weber W, Tap W et al. Change in quantitative FDG–PET was significantly more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high grade soft tissue sarcomas. Presented at: Am. Soc. Clin. Oncol. Chicago, IL, USA 1–5 June, 2007.
   Google Scholar
• Ventura A, Kirsch DG, McLaughlin ME et al. Restoration of p53 function leads to tumour regression in vivo.Nature445, 661–665 (2007).
   PubMed Web of Science ®Google Scholar
• Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat. Rev. Drug Disc.5(7), 577–584 (2006).
   PubMed Web of Science ®Google Scholar
• Gallinari P, Di Marco S, Jones P et al. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res.17, 195–211 (2007).
   PubMed Web of Science ®Google Scholar
• Fuji N, You L, Xu Z et al. An antagonist of dishevelled protein–protein interaction suppresses β-catenin-dependent tumor cell growth. Cancer Res.67(2), 573–579 (2007).
   PubMedGoogle Scholar
• Haluska P, Carboni JM, Loegering DA et al.In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res.66(1), 362–371 (2006).
   PubMed Web of Science ®Google Scholar
• Shor AS, Keschman EA, Lee FY et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res.67(6), 2800–2808 (2007).
   PubMed Web of Science ®Google Scholar
• Ying H, Biroc SL, Li W et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol. Cancer Ther.5(9), 2158–2164 (2006).
   PubMedGoogle Scholar
• Toub N, Bertrand JR, Tamaddon A et al. Efficacy of siRNA nanocapsules targeted against the EWS-FLI1 oncogene in Ewing sarcoma. Pharm. Res.23(5), 892–900 (2006).
   PubMed Web of Science ®Google Scholar
• Bernasconi M, Remppis, Fredericks WJ et al. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc. Natl Acad. Sci. USA93(23), 13164–13169 (1996).
   PubMed Web of Science ®Google Scholar
• Chansky HA, Barahmand-Pour F, Mei Q et al. Targeting of EWS/FLI-1 RNA intererference attenuates tumor phenotype of Ewing’s sarcoma cells in vitro.J. Orthop. Res.22(4), 910–917 (2004).
   PubMed Web of Science ®Google Scholar
• Dohjima T, Lee NS, Li H et al. Small interfering RNAs expressed from a Pol II promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol. Ther.7(6), 811–816 (2003).
   PubMed Web of Science ®Google Scholar